Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells

@article{Bentel1999AndrogenRA,
  title={Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells},
  author={J. Bentel and S. Birrell and Marie A. Pickering and Duncan J Holds and W. Tilley},
  journal={Molecular and Cellular Endocrinology},
  year={1999},
  volume={154},
  pages={11-20}
}
Medroxyprogesterone acetate (MPA), which is frequently used as second line hormonal therapy for the treatment of metastatic breast cancer, binds with high affinity to the progesterone receptor (PR). However, the androgenic side-effects of MPA suggest that it may also activate androgen receptor (AR) regulated pathways. Treatment of the human breast cancer cell lines MDA-MB-453, ZR-75-1 and T47-D with high dose (100 nM) MPA resulted in 26-30% inhibition of cell growth, which was partially… Expand
Molecular and structural basis of androgen receptor responses to dihydrotestosterone, medroxyprogesterone acetate and Δ4-tibolone
Induction of androgen receptor activity by norgestimate and norelgestromin in MDA-MB 231 breast cancer cells
Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.
Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Androgens induce divergent proliferative responses in human breast cancer cell lines
Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.
...
1
2
3
4
...